Here are the 10-K annual reports from NextCure, Inc. (NXTC) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow NXTC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NXTC filings page.
NextCure, Inc. is a clinical-stage biopharmaceutical company focused on antibody-drug conjugates to treat cancers that do not respond to current therapies. Its two lead candidates are SIM0505, a CDH6-targeted ADC licensed from Zaiming, and LNCB74, a B7-H4-targeted ADC co-developed with LigaChem.
SIM0505 and LNCB74 are both in Phase 1 trials, with early data updates planned in 2026. NextCure restructured operations in March 2024, pausing internal manufacturing and reducing its workforce to align with this focused pipeline. The company reported a net loss of $55.8 million in 2025, an accumulated deficit of $436.0 million, a non‑affiliate market value of about $12.6 million as of mid‑2025, and states it will need substantial additional capital. It holds an intellectual property portfolio expected to provide patent protection for LNCB74 and SIM0505 into 2039 and 2044, respectively.